Want to join the conversation?
$MRK announced efficacy and safety data in previously untreated adults with HIV-1 infection for its investigational once-daily formulation of Isentress (raltegravir), known as raltegravir 600 mg, from the ongoing Phase 3 pivotal trial called ONCEMRK. The study found raltegravir is non-inferior efficacy and safety to a regimen.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)